Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
Nestle S.A. ( OTCPK:NSRGY ) subsidiary Galderma announces positive results from a Phase 2 clinical trial evaluating QM1114, its ready-to-use liquid formulation of botulinum toxin type A, for the treatment of glabellar lines (frown lines). More news on: Nestlé S.A., Allergan plc, Evo...
Presentations demonstrate promising advances for the treatment of advanced hepatocellular carcinoma, metastatic pancreatic cancer and neuroendocrine tumors Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that clinical trials with cabozantinib (Cabometyx ® ) in...
Topline results from a Phase 3b/4 study, ENGAGE , evaluating Ipsen's ( OTCPK:IPSEY ) Dysport (abobotulinumtoxinA) in adult patients with both upper and lower limb spasticity along with a Guided Self-Rehabilitation Contract, showed a treatment benefit. The data are being presented at the ...
Results from a matching-adjusted indirect comparison (MAIC) suggest that cabozantinib provides two additional months of progression-free survival versus regorafenib in the second-line treatment of advanced hepatocellular carcinoma 1 Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY...
Initial data from Part 1 of a Phase 2/3 clinical trial, RESILIENT , evaluating Ipsen's ( OTCPK:IPSEY -1.4% ) Onivyde (irinotecan liposome injection) in small cell lung cancer (SCLC) patients who progressed following initial treatment with platinum-based chemo showed a treatment effect....
– 44% of patients achieved a response and nearly half (48%) maintained disease control at week 12 (efficacy as secondary endpoint) – – Treatment emergent adverse events Grade 3 or higher were reported by 10 of 25 patients (safety as primary endpoint) – Regu...
Ipsen S.A. ADR (IPSEY) Q2 2019 Results Earnings Conference Call July 25, 2019, 08:30 AM ET Company Participants David Meek - CEO Aymeric Chatelier - EVP and CFO Conference Call Participants Emily Field - Barclays Thibault Boutherin - Morgan Stanley Luisa Hector - Exane BN...
The following slide deck was published by Ipsen S.A. in conjunction with their 2019 Q2 earnings Read more ...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced financial results for the first half of 2019. Extract of audited consolidated results for H1 2019 and 2018 David Meek, Chief Executive Officer of Ipsen , state...
– Treatment emergent adverse events Grade 3 or higher were reported by 20 of 32 patients from the 50/60 dose pooled patient analysis; no patient reported Grade 3 or higher fatigue or peripheral neuropathy (primary endpoint) – – Approximately three quarters of patients...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...